TSE:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aeterna Zentaris Stock (TSE:AEZS) Get Aeterna Zentaris alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1,232 shsAverage Volume1,137 shsMarket CapitalizationC$25.37 millionP/E RatioN/ADividend Yield2.79%Price TargetN/AConsensus RatingN/A Company Overview Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. Read More Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AEZS Stock News HeadlinesClosing Bell: Aeterna Zentaris Inc up on Monday (AEZS)July 29, 2024 | theglobeandmail.comAEZS:CA Aeterna Zentaris Inc.July 29, 2024 | seekingalpha.comAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days. | Freedom Financial (Ad)Closing Bell: Aeterna Zentaris Inc flat on Friday (AEZS)July 19, 2024 | theglobeandmail.comCeapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna MergerMay 29, 2024 | finance.yahoo.comCancer Cachexia Pipeline Insights Report, 2024 Featuring Emerging Drugs Macimorelin (AEterna Zentaris) and PF-06946860 (Pfizer)May 22, 2024 | finance.yahoo.comAeterna Zentaris Finalizes Some Details for Ceapro MergerMay 17, 2024 | finance.yahoo.comAEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)May 1, 2024 | theglobeandmail.comSee More Headlines AEZS Stock Analysis - Frequently Asked Questions How do I buy shares of Aeterna Zentaris? Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Meta Platforms (META), Novavax (NVAX), Verizon Communications (VZ), Western Uranium & Vanadium (WUC), Air Canada (AC), Affirm (AFRM) and AutoZone (AZO). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:AEZS CIKN/A Webwww.aezsinc.com Phone18439003223FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$18.05 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.71% Return on Assets-29.96% Debt Debt-to-Equity Ratio1.80 Current Ratio5.94 Quick Ratio9.37 Sales & Book Value Annual SalesC$2.37 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.46 Book ValueC$10.68 per share Price / BookN/AMiscellaneous Outstanding Shares3,060,000Free FloatN/AMarket CapC$25.37 million OptionableNot Optionable Beta2.26 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (TSE:AEZS) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredWhat most options traders never learn before their first tradeMost options losses don't come from picking the wrong trade - they come from traders who never understood how ...Base Camp Trading | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.